Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.35 |
| ▸ | NOS2 | P35228 | 5/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254648 | 0.94 | GBA1 (0.33) | NOS1NOS2NOS3MAOAMAOB | |
| SCHEMBL3254586 | 0.92 | ALDH1A1 (0.36) | GLB1 | |
| SCHEMBL789308 | 0.89 | — | — | |
| SCHEMBL10701436 | 0.84 | SPHK2 (0.35) | NOS1MAOAMAOB | |
| SCHEMBL10702646 | 0.82 | SCN2A (0.34) | NOS1NOS2 | |
| SCHEMBL8026346 | 0.82 | CHRM1 (0.37) | MAOAMAOB | |
| SCHEMBL3715413 | 0.81 | SCN2A (0.36) | NOS1NOS2GLB1 | |
| SCHEMBL459100 | 0.80 | — | — | |
| SCHEMBL8042080 | 0.80 | MAOA (0.31) | MAOAMAOB | |
| SCHEMBL6266022 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110128373-B | Piperazinyl tin complex, preparation method thereof, thin film and solar cell | 鸿翌科技有限公司 | 2023-03-24 | — | — | CN | claimed |
| US-4279912-A | ANTIALLERGENS, BRONCHODILATORS | ROUSSEL UCLAF (FR) | 1981-07-21 | — | — | US | claimed |
| US-4091115-A | ANTIDEPRESSANTS | ROUSSEL UCLAF (FR) | 1978-05-23 | — | — | US | claimed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| EP-3833352-A2 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | University of Central Florida Research Foundation, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-31 | — | — | US | disclosed |
| WO-2020033944-A2 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| EP-3311813-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-08-07 | — | — | EP | disclosed |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| US-10064879-B2 | Method for treating depression and/or depression status with substituted quinoxaline compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-09-04 | — | — | US | disclosed |
| EP-0275381-A2 | Dye transfer process | BASF Aktiengesellschaft (DE) | 1988-07-27 | — | — | EP | disclosed |
| US-4760049-A | Dye transfer | BASF AKTIENGESELLSCHAFT (DE) | 1988-07-26 | — | — | US | disclosed |
| EP-0273307-A2 | Method of transferring cationic dyes in their de-protonated, electrically neutral form | BASF Aktiengesellschaft (DE) | 1988-07-06 | — | — | EP | disclosed |
| US-4649149-A | ANTHELMINTICS | CIBA-GEIGY CORPORATION (US) | 1987-03-10 | — | — | US | disclosed |
| US-4511567-A | ANTHELMINTICS | CIBA-GEIGY CORPORATION (US) | 1985-04-16 | — | — | US | disclosed |
| US-4279912-A | ANTIALLERGENS, BRONCHODILATORS | ROUSSEL UCLAF (FR) | 1981-07-21 | — | — | US | disclosed |
| US-4154852-A | ANTIDEPRESSANTS | ROUSSEL UCLAF (FR) | 1979-05-15 | — | — | US | disclosed |
| US-4145419-A | ANTIALLERGENS, BRONCHODILATORS | ROUSSEL UCLAF (FR) | 1979-03-20 | — | — | US | disclosed |
| US-4091115-A | ANTIDEPRESSANTS | ROUSSEL UCLAF (FR) | 1978-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | NOS1 2208/4885NOS2 1743/4885NOS3 1868/4885 |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | NOS1 386/4885NOS2 646/4885NOS3 283/4885 |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | NOS1 365/4885NOS2 499/4885NOS3 284/4885 |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | MC2R, PNMT, SLC6A2 | NOS1 465/4885NOS2 701/4885NOS3 398/4885 |
| US-10064879-B2 | Method for treating depression and/or depression status with substituted quinoxaline compounds | KYNU, CRH, CHRM1 | NOS1 547/4885NOS2 535/4885NOS3 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.